Kvistgård, Denmark, January 27, 2010 - Bavarian Nordic A/S (OMX: BAVA) publishes
today a prospectus supplement (the "Prospectus Supplement") which contains
information regarding Bavarian Nordic A/S's pending suit against Oxford
BioMedica as described in prospectus of 8 January 2010 (the "Prospectus") and
should be read and construed in conjunction with the Prospectus. The Prospectus
Supplement is considered to be incorporated in and to make up a component of the
Prospectus.

Prospectus supplement
Following publication the Prospectus Supplement will be available for inspection
at Bavarian Nordic A/S' office, Hejreskovvej 10A, DK-3490 Kvistgaard, Denmark.
The Prospectus Supplement is furthermore available on the website - except to
persons subject to legislation prohibiting this - at www.bavarian-nordic.com,
and will be available from:


 Nordea Bank Danmark A/S        SEB Enskilda, Copenhagen Branch
 Securities Operations/HH7324   Silkegade 8
 P. O. Box 850                  DK-1113 Copenhagen K
 DK-0900 København C            Tlf.: +45 36 97 74 00
 Tlf.: +45 33 33 50 92          E-mail: prospekt@enskilda.dk
 E-mail: prospekt.ca@nordea.com


Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64

Not for release, publication or distribution, directly or indirectly in or into
Australia, Canada, Japan or the United States
This announcement does not constitute or form part of an offer to sell or the
solicitation of an offer to buy the securities of Bavarian Nordic A/S (the
"Securities") in Australia, Canada, Japan or the United States or in any other
jurisdiction. The Securities may not be offered or sold in the United States
absent registration or an exemption from registration under the U.S. Securities
Act of 1933, as amended. The issuer of the Securities has not registered, and
does not intend to register, any portion of the Offering in the United States or
in any jurisdiction outside Denmark and the United Kingdom, and does not intend
to conduct a public offering of the Securities in the United States or in any
jurisdiction outside Denmark and the United Kingdom. Copies of this announcement
are not being made and may not be distributed or sent into Australia, Canada,
Japan or the United States.

Forward-looking statements
This announcement includes "forward-looking statements" that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.

About Bavarian Nordic
Bavarian Nordic A/S is a leading industrial biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline is focused in
the three areas; biodefence, cancer and infectious diseases, and includes seven
development programmes. Two programmes are under preparation for Phase III:
IMVAMUNE®, a third-generation smallpox vaccine is being developed under a
contract with the US government, and PROSTVAC(TM), a therapeutic vaccine for
advanced prostate cancer is being developed under a collaboration agreement with
the National Cancer Institute.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit www.bavarian-nordic.com
<http://www.bavarian-nordic.com/>





[HUG#1377505]





    2010-09-uk: http://hugin.info/100065/R/1377505/338397.pdf